Form 4: Anika Therapeutics Director William Jellison Reports Stock Transactions
SEC Form 4 Filing
Director William Jellison reports acquisition of restricted stock units and transfer of common stock to a revocable trust.
Summary
- On July 9, 2024, William Jellison, a director of Anika Therapeutics, Inc., reported acquiring 5,771 restricted stock units (RSUs).
- These RSUs vest in full on the earlier of the 2025 annual meeting or July 9, 2025.
- Each RSU represents the right to receive one share of Anika Therapeutics common stock.
- Jellison also reported transferring 2,700 shares of common stock to the Amended and Restated William R. Jellison Trust dated July 3, 2018, of which he is a beneficiary and trustee.
- Following these transactions, Jellison directly owns 6,239 shares of common stock.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing and does not convey any particularly positive or negative sentiment. It simply reports transactions.
Industry Context
This filing is a routine disclosure of stock transactions by a company insider, which is a common practice in publicly traded companies. It provides transparency to investors regarding the ownership positions and trading activities of key individuals within the company.
Stakeholder Impact
- The transactions provide transparency to shareholders regarding insider activity.
Key Dates
| Date | Description |
|---|---|
| July 3, 2018 | Date of the Amended and Restated William R. Jellison Trust |
| July 9, 2024 | Date of stock transactions (RSU acquisition and stock transfer) |
| July 9, 2025 | RSUs vest in full on the earlier of the 2025 annual meeting of the Company's stockholders or July 9, 2025 |
| July 11, 2024 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.